Vnitr Lek 2023, 69(7):460-465 | DOI: 10.36290/vnl.2023.089

Neurological complications of diabetes mellitus

Eva Vlčková
Lékařská fakulta Masarykovy univerzity, Neurologická klinika Fakultní nemocnice Brno

The most important microvascular neurological complication of diabetes mellitus is diabetic neuropathy. In addition to the most common distal sensory or sensory-motor polyneuropathy, this term also includes autonomic neuropathy and a number of focal forms (mononeuropathy, plexopathy). Diagnosis is based on history and clinical examination; the choice of other diagnostic methods (nerve conduction studies and needle electromyography, autonomic nerve function tests, assessment of intraepidermal innervation from skin biopsy, etc.) depends on the type of nerve fibers affected. The basic intervention in the therapy and prevention of the development and progression of diabetic neuropathy is long-term optimal control of diabetes and other cardiovascular risk factors, and physical activity. In painful forms, drugs affecting neuropathic pain are also used, i.e. antiepileptics from the group of modulators of the α2δ subunit of calcium channels (gabapentin, pregabalin) and antidepressants from the group of serotonin and noradrenaline reuptake inhibitors (duloxetine, venlafaxine) or tricyclic antidepressants (amitriptyline). Thioctic acid (alpha-lipoic acid) and a number of opioids also have an analgesic effect. Diabetes mellitus is also an independent cerebrovascular risk factor and thus contributes to the development of ischaemic stroke. It also significantly increases the risk of developing cognitive impairment.

Keywords: diabetes mellitus, polyneuropathies, mononeuropathies, neuropathic pain, cerebrovascular disorders, stroke, cognitive dysfunction.

Accepted: October 19, 2023; Published: October 26, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlčková E. Neurological complications of diabetes mellitus. Vnitr Lek. 2023;69(7):460-465. doi: 10.36290/vnl.2023.089.
Download citation

References

  1. Pop­‑Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. doi:10.2337/dc16-2042 Go to original source... Go to PubMed...
  2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes research and clinical practice. 2019;157:107843. doi:10.1016/j.diabres.2019.107843 Go to original source... Go to PubMed...
  3. Yavuz DG. Classification, risk factors, and clinical presentation diabetic neuropathy. In: Tavakoli M (ed). Diabetic neuropathy (1st ed.). Elsevier: Amsterdam (NL) 2022: 1-9. ISBN 9780128206706. doi: 10.1016/B978-0-12-820669-0.00024-4. Go to original source...
  4. ElSayed NA, Aleppo G, Aroda VR, et al. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023. Diabetes care 2023;46(Suppl 1):S203-S215. doi:10.2337/dc23-S012 Go to original source... Go to PubMed...
  5. Callaghan BC, Gallagher G, Fridman V, et al. Diabetic neuropathy: what does the future hold? Diabetologia 2020;63(5):891-897. doi:10.1007/s00125-020-05085-9 Go to original source... Go to PubMed...
  6. Tavakoli M, Gogas Yavuz D, et al. Diabetic Neuropathy: Current Status and Future Prospects. Journal of diabetes research 2017;2017:5825971. doi:10.1155/2017/5825971 Go to original source... Go to PubMed...
  7. Bondar A, Popa AR, Papanas N, et al. Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review). Exp Ther Med 2021;22(1):690. doi: 10.3892/etm.2021.10122. Go to original source... Go to PubMed...
  8. Jirkovská A (ed.), et al. Syndrom diabetické nohy - prevence, diagnostika a terapie. Geum: Praha 2022. ISBN 978-80-87969-61-8
  9. Feldman EL, Callaghan BC, Pop­‑Busui R, et al. Diabetic neuropathy. Nat Rev Dis Prim 2019;5(1):1-21. doi:10.1038/s41572-019-0092-1 Go to original source... Go to PubMed...
  10. Boussageon R, Bejan­‑Angoulvant T, Saadatian­‑Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta­‑analysis of randomised controlled trials. BMJ 2011;343:d4169. doi: 10.1136/bmj.d4169. Go to original source... Go to PubMed...
  11. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012;(6):CD007543. doi: 10.1002/14651858.CD007543.pub2. Go to original source... Go to PubMed...
  12. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre­‑diabetic neuropathy. Diabetes Care 2006;29(6):1294-9. Go to original source... Go to PubMed...
  13. Kluding PM, Bareiss SK, Hastings M, et al. Physical Training and Activity in People With Diabetic Peripheral Neuropathy: Paradigm Shift. Phys Ther 2017;97(1):31-43. doi: 10.2522/ptj.20160124. Go to original source... Go to PubMed...
  14. Lewis EJH, Perkins BA, Lovblom LE, et al. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. Neurology 2017;88(24):2294-2301. doi:10.1212/WNL.0000000000004033 Go to original source... Go to PubMed...
  15. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta­‑analysis. Lancet Neurol 2015;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Go to original source... Go to PubMed...
  16. Vlčková E. Současné možnosti léčby neuropatické bolesti. ProfiMedicína 2022;15:4-8.
  17. Bednařík J, Ambler Z, Opavský J, et al. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93-101.
  18. Maida CD, Daidone M, Pacinella G, et al. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. International Journal of Molecular Sciences 2022; 23(4):2397. doi: 10.3390/ijms23042397 Go to original source... Go to PubMed...
  19. Sebastian MJ, Khan SK, Pappachan JM, et al. Diabetes and cognitive function: An evidence­‑based current perspective. World J Diabetes 2023;14(2):92-109. doi: 10.4239/wjd.v14.i2. 92. Go to original source...
  20. Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta­‑analysis of 144 prospective studies. Ageing Res Rev 2019;55:100944. doi:10.1016/j.arr.2019.100944 Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.